By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CureVac GmbH 

Paul-Ehrlich-Str. 15

Tübingen    72076  Germany
Phone: 49-7071-92053-0 Fax: 49-7071-92053-11



Company News
CureVac Announces Publication In The Lancet Of First-Ever Human Proof-Of-Concept Study Investigating The Safety And Immunogenicity Of A Prophylactic mRNA Vaccine 7/26/2017 6:29:27 AM
CureVac To Receive Patent Claiming The Combination Of mRNA Vaccines With Anti-PD-1 Antibodies 7/20/2017 6:59:31 AM
CureVac Expands GMP Production Capacities For RNA Products 6/26/2017 11:18:58 AM
CureVac Extends Global Intellectual Property Estate For Prophylactic mRNA Vaccines 6/13/2017 8:48:40 AM
CureVac Appoints Daniel Menichella As CEO Of CureVac Inc., The Company's U.S. Subsidiary 5/2/2017 8:53:20 AM
JPM17: CureVac Release: Biotech's mRNA Program Fails Phase II Test, Putting Spotlight on Other Biotechs Like Moderna 1/12/2017 5:45:05 AM
Study With CureVac's RNAdjuvant Technology Published In Cancer Immunology, Immunotherapy, Demonstrates Equal Responsiveness Of Blood Cells From Both Hepatocellular Carcinoma (HCC) Patients And Healthy Subjects To The RNA-Based Adjuvant 12/5/2016 6:57:53 AM
CureVac Secures An Additional $29.5 Million From Two New Investors 11/9/2016 12:54:16 PM
CureVac Receives Broad Patent For RNAntibody Technology 11/9/2016 11:56:18 AM
CureVac Appoints Pierre Kemula As Chief Financial Officer 10/11/2016 6:36:11 AM